What is Coremap?
Coremap is at the forefront of developing advanced technology for the diagnosis and treatment of atrial fibrillation (AF), a critical condition involving irregular heartbeats that can lead to severe health issues. The company's innovative solutions empower physicians with enhanced visualization capabilities for AF, thereby improving patient treatment outcomes. Coremap's commitment to advancing research and innovation in AF management is supported by a distinguished team of medical and biomedical engineering experts and advisors.
How much funding has Coremap raised?
Coremap has raised a total of $33.5M across 2 funding rounds:
Series A
$10.5M
Series B
$23M
Series A (2020): $10.5M with participation from Ronny Ginor and Qure Ventures
Series B (2022): $23M led by Russ Scully and Qure Ventures
Key Investors in Coremap
Qure Ventures
Qure Ventures is Israel's first exclusively focused digital health fund, investing in startups within the country's leading tech and digital health ecosystem. The company aims to revolutionize medicine through digital health solutions, addressing the growing healthcare demands of an aging global population. With strategic partnerships across consumer, provider, payer, and pharma domains, Qure provides its portfolio companies with fast track access to market and clinical trial opportunities. Led by experienced digital health veterans, Qure Ventures is committed to making a significant impact on health and wellbeing for current and future generations.
Russ Scully
Undisclosed investor participating in the funding round.
Ronny Ginor
Undisclosed investor participating in the funding round.
What's next for Coremap?
The substantial enterprise-level funding, including a recent major strategic investment, positions Coremap for accelerated growth and market expansion. This capital infusion is expected to fuel further research and development, enhance product commercialization, and potentially broaden the company's reach within the digital health and medical device landscape. The company's trajectory suggests a focus on scaling its operations and solidifying its position as a leader in AF diagnostic and treatment technologies.
See full Coremap company page
